Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
inhibits microtubule depolymerization
|
| gptkbp:appointed_by |
oncology
intravenous infusion |
| gptkbp:approves |
gptkb:1996
gptkb:FDA |
| gptkbp:brand |
gptkb:Taxotere
|
| gptkbp:can_be_used_with |
gptkb:cisplatin
gptkb:carboplatin gptkb:doxorubicin |
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
severe liver impairment
neutrophil count less than 1500/mm³ |
| gptkbp:developed_by |
gptkb:taxus_baccata
|
| gptkbp:discovered_by |
gptkb:Aventis
|
| gptkbp:dissolved |
insoluble in water
soluble in ethanol soluble in dimethyl sulfoxide |
| gptkbp:excretion |
urine
bile |
| https://www.w3.org/2000/01/rdf-schema#label |
docetaxel
|
| gptkbp:ingredients |
C43 H53 N3 O10 S
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:is_atype_of |
L01 C D02
|
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count renal function tests |
| gptkbp:is_used_for |
treating breast cancer
treating prostate cancer treating lung cancer treating stomach cancer |
| gptkbp:lifespan |
35 hours
|
| gptkbp:manager |
IV
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:provides_information_on |
weekly administration
every 3 weeks |
| gptkbp:research_areas |
cancer therapy
combination therapy pharmacogenomics adverse effects drug resistance clinical efficacy |
| gptkbp:side_effect |
fatigue
nausea diarrhea hair loss neutropenia |
| gptkbp:storage |
room temperature
|
| gptkbp:type_of |
114977-28-5
|
| gptkbp:weight |
807.96 g/mol
|
| gptkbp:bfsParent |
gptkb:Herceptin
|
| gptkbp:bfsLayer |
4
|